Skip to Content

Victrelis Approval History

  • FDA approved: Yes (First approved May 13th, 2011)
  • Brand name: Victrelis
  • Generic name: boceprevir
  • Company: Merck & Co., Inc.
  • Treatment for: Hepatitis C

Victrelis (boceprevir) is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated for the treatment of chronic hepatitis C.

Development History and FDA Approval Process for Victrelis

May 14, 2011Approval FDA Approves Merck's Victrelis (boceprevir), First-in-Class Oral Hepatitis C Virus (HCV) Protease Inhibitor
Apr 28, 2011Victrelis (boceprevir) Unanimously Recommended for Approval By FDA Advisory Committee for Treatment of Chronic HCV Genotype 1 Infection
Jan  6, 2011Boceprevir, Merck's Investigational Oral Hepatitis C Protease Inhibitor, Receives FDA Priority Review and EMA Accelerated Assessment

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.